Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 47 | 2024 | 277 | 10.430 |
Why?
|
| Mass Screening | 20 | 2024 | 462 | 3.620 |
Why?
|
| Early Detection of Cancer | 17 | 2024 | 336 | 3.340 |
Why?
|
| Zambia | 30 | 2024 | 40 | 3.050 |
Why?
|
| Breast Neoplasms | 22 | 2024 | 1502 | 2.860 |
Why?
|
| Uterine Cervical Dysplasia | 9 | 2024 | 39 | 1.840 |
Why?
|
| Female | 78 | 2024 | 20969 | 1.540 |
Why?
|
| HIV Infections | 16 | 2022 | 2303 | 1.370 |
Why?
|
| Papillomavirus Infections | 10 | 2024 | 336 | 1.330 |
Why?
|
| Developing Countries | 9 | 2023 | 99 | 1.290 |
Why?
|
| Humans | 84 | 2024 | 37093 | 1.200 |
Why?
|
| Community Health Planning | 4 | 2018 | 35 | 1.180 |
Why?
|
| Medical Oncology | 3 | 2024 | 30 | 1.130 |
Why?
|
| Neoplasms | 8 | 2023 | 1103 | 1.060 |
Why?
|
| Adult | 35 | 2024 | 11712 | 0.970 |
Why?
|
| Ultrasonography, Mammary | 2 | 2020 | 6 | 0.950 |
Why?
|
| Middle Aged | 32 | 2024 | 10129 | 0.950 |
Why?
|
| Gynecology | 1 | 2024 | 31 | 0.930 |
Why?
|
| Primary Health Care | 2 | 2024 | 294 | 0.920 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 66 | 0.880 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 560 | 0.850 |
Why?
|
| Cryotherapy | 5 | 2021 | 9 | 0.760 |
Why?
|
| Africa South of the Sahara | 14 | 2024 | 46 | 0.750 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 61 | 0.740 |
Why?
|
| Health Promotion | 4 | 2019 | 653 | 0.710 |
Why?
|
| Algorithms | 2 | 2024 | 465 | 0.700 |
Why?
|
| Prospective Studies | 12 | 2024 | 1378 | 0.690 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 27 | 0.690 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2018 | 864 | 0.650 |
Why?
|
| Program Evaluation | 3 | 2015 | 339 | 0.640 |
Why?
|
| Breast Diseases | 1 | 2018 | 6 | 0.640 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 494 | 0.630 |
Why?
|
| Delivery of Health Care | 7 | 2022 | 276 | 0.630 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 275 | 0.630 |
Why?
|
| Rural Health Services | 1 | 2018 | 44 | 0.620 |
Why?
|
| Program Development | 3 | 2015 | 233 | 0.610 |
Why?
|
| Vaginal Smears | 5 | 2011 | 57 | 0.590 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2013 | 215 | 0.550 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 47 | 0.540 |
Why?
|
| Acetic Acid | 4 | 2021 | 16 | 0.530 |
Why?
|
| Papillomaviridae | 6 | 2019 | 127 | 0.500 |
Why?
|
| Referral and Consultation | 4 | 2024 | 117 | 0.470 |
Why?
|
| Incidence | 7 | 2024 | 922 | 0.470 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 6 | 0.470 |
Why?
|
| Women's Health | 6 | 2016 | 145 | 0.460 |
Why?
|
| Socioeconomic Factors | 7 | 2024 | 1067 | 0.450 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 49 | 0.440 |
Why?
|
| United States | 9 | 2024 | 4223 | 0.440 |
Why?
|
| Telemedicine | 2 | 2020 | 182 | 0.430 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 562 | 0.420 |
Why?
|
| Poverty | 4 | 2022 | 348 | 0.420 |
Why?
|
| Preventive Health Services | 2 | 2012 | 64 | 0.410 |
Why?
|
| Health Resources | 1 | 2011 | 32 | 0.390 |
Why?
|
| Rural Population | 6 | 2024 | 294 | 0.360 |
Why?
|
| Health Status Disparities | 2 | 2024 | 642 | 0.350 |
Why?
|
| Health Care Coalitions | 2 | 2006 | 11 | 0.340 |
Why?
|
| Attitude to Health | 3 | 2012 | 325 | 0.340 |
Why?
|
| Peer Group | 1 | 2010 | 156 | 0.330 |
Why?
|
| Reproductive Health Services | 1 | 2008 | 10 | 0.320 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 215 | 0.320 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2008 | 26 | 0.320 |
Why?
|
| Cohort Studies | 9 | 2023 | 1492 | 0.310 |
Why?
|
| Cervix Uteri | 3 | 2015 | 42 | 0.310 |
Why?
|
| Computer Simulation | 2 | 2021 | 362 | 0.310 |
Why?
|
| Social Justice | 1 | 2007 | 55 | 0.300 |
Why?
|
| Prognosis | 4 | 2024 | 739 | 0.290 |
Why?
|
| Aged | 10 | 2024 | 6741 | 0.290 |
Why?
|
| Ovarian Neoplasms | 3 | 2005 | 312 | 0.290 |
Why?
|
| Cooperative Behavior | 3 | 2019 | 219 | 0.280 |
Why?
|
| Healthy People Programs | 1 | 2006 | 23 | 0.280 |
Why?
|
| Community Health Services | 1 | 2007 | 185 | 0.270 |
Why?
|
| Survival Analysis | 5 | 2024 | 325 | 0.260 |
Why?
|
| Electrosurgery | 2 | 2019 | 2 | 0.260 |
Why?
|
| Colposcopy | 2 | 2015 | 13 | 0.260 |
Why?
|
| Dairy Products | 1 | 2005 | 35 | 0.250 |
Why?
|
| Reproduction | 1 | 2005 | 71 | 0.250 |
Why?
|
| Clinical Competence | 2 | 2021 | 130 | 0.250 |
Why?
|
| HIV Seropositivity | 2 | 2018 | 190 | 0.250 |
Why?
|
| ROC Curve | 1 | 2024 | 138 | 0.240 |
Why?
|
| Life Expectancy | 1 | 2024 | 42 | 0.230 |
Why?
|
| Demography | 2 | 2015 | 175 | 0.230 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 70 | 0.230 |
Why?
|
| History, 20th Century | 1 | 2024 | 117 | 0.230 |
Why?
|
| Radiotherapy | 1 | 2002 | 18 | 0.220 |
Why?
|
| Photography | 2 | 2015 | 46 | 0.220 |
Why?
|
| Blood Transfusion | 1 | 2002 | 27 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2003 | 56 | 0.220 |
Why?
|
| Income | 4 | 2022 | 140 | 0.210 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.210 |
Why?
|
| Interleukin-10 | 1 | 2002 | 75 | 0.210 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2002 | 25 | 0.210 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 35 | 0.210 |
Why?
|
| Shoulder | 1 | 2021 | 9 | 0.210 |
Why?
|
| Arm | 1 | 2021 | 28 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 400 | 0.200 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 11 | 0.200 |
Why?
|
| Dendritic Cells | 1 | 2002 | 113 | 0.200 |
Why?
|
| Uterine Neoplasms | 1 | 2002 | 39 | 0.200 |
Why?
|
| Child, Orphaned | 1 | 2021 | 3 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2002 | 95 | 0.190 |
Why?
|
| Democratic Republic of the Congo | 1 | 2020 | 5 | 0.190 |
Why?
|
| Prevalence | 5 | 2015 | 1455 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 251 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 11 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 18 | 0.190 |
Why?
|
| Receptor, erbB-2 | 1 | 2002 | 133 | 0.190 |
Why?
|
| Africa | 4 | 2022 | 76 | 0.190 |
Why?
|
| Male | 8 | 2024 | 20025 | 0.180 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 217 | 0.180 |
Why?
|
| Adolescent | 9 | 2022 | 5363 | 0.180 |
Why?
|
| Learning | 1 | 2021 | 117 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2020 | 208 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 17 | 0.180 |
Why?
|
| Breast | 1 | 2020 | 135 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2019 | 2026 | 0.170 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2019 | 7 | 0.170 |
Why?
|
| Obesity | 1 | 2007 | 1067 | 0.170 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 539 | 0.160 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 39 | 0.160 |
Why?
|
| Diet | 1 | 2005 | 801 | 0.160 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 35 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2015 | 753 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2022 | 400 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 358 | 0.150 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 146 | 0.140 |
Why?
|
| Alabama | 3 | 2006 | 51 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 2721 | 0.130 |
Why?
|
| Uterine Cervical Diseases | 1 | 2015 | 14 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 935 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2015 | 50 | 0.130 |
Why?
|
| Observer Variation | 1 | 2015 | 52 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 82 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2018 | 322 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 14 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2015 | 105 | 0.130 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 5 | 0.130 |
Why?
|
| Mississippi | 2 | 2007 | 122 | 0.130 |
Why?
|
| Papillomavirus Vaccines | 2 | 2015 | 151 | 0.120 |
Why?
|
| Logistic Models | 2 | 2017 | 923 | 0.120 |
Why?
|
| Cytological Techniques | 1 | 2014 | 15 | 0.120 |
Why?
|
| Pregnancy | 3 | 2023 | 1549 | 0.120 |
Why?
|
| Topography, Medical | 1 | 2013 | 2 | 0.120 |
Why?
|
| South Africa | 3 | 2022 | 35 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 229 | 0.120 |
Why?
|
| Sex Education | 1 | 2013 | 30 | 0.120 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 38 | 0.110 |
Why?
|
| Probability | 1 | 2013 | 78 | 0.110 |
Why?
|
| HIV | 1 | 2013 | 98 | 0.110 |
Why?
|
| Social Class | 2 | 2016 | 247 | 0.110 |
Why?
|
| Fertility | 2 | 2023 | 59 | 0.110 |
Why?
|
| Survival Rate | 2 | 2020 | 311 | 0.100 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 37 | 0.100 |
Why?
|
| Child | 4 | 2022 | 3131 | 0.100 |
Why?
|
| Metagenome | 1 | 2012 | 29 | 0.100 |
Why?
|
| Age Factors | 1 | 2015 | 1033 | 0.100 |
Why?
|
| Vagina | 1 | 2012 | 81 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 583 | 0.100 |
Why?
|
| Killer Cells, Natural | 2 | 2002 | 92 | 0.100 |
Why?
|
| Urban Population | 3 | 2024 | 333 | 0.100 |
Why?
|
| Patient Preference | 1 | 2012 | 44 | 0.100 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 14 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2006 | 113 | 0.100 |
Why?
|
| Patient Participation | 1 | 2012 | 75 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2011 | 21 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2002 | 399 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 404 | 0.090 |
Why?
|
| Young Adult | 6 | 2016 | 4268 | 0.090 |
Why?
|
| Minority Groups | 2 | 2007 | 596 | 0.090 |
Why?
|
| Education | 1 | 2010 | 55 | 0.090 |
Why?
|
| Nurses | 1 | 2010 | 48 | 0.090 |
Why?
|
| Focus Groups | 2 | 2012 | 348 | 0.090 |
Why?
|
| Data Collection | 1 | 2010 | 194 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2015 | 1369 | 0.090 |
Why?
|
| Beneficence | 1 | 2007 | 2 | 0.080 |
Why?
|
| Quality of Life | 2 | 2016 | 481 | 0.080 |
Why?
|
| Biopsy | 1 | 2008 | 164 | 0.080 |
Why?
|
| Personal Autonomy | 1 | 2007 | 18 | 0.080 |
Why?
|
| Risk Factors | 3 | 2021 | 3562 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 974 | 0.070 |
Why?
|
| Community-Institutional Relations | 2 | 2006 | 187 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 893 | 0.070 |
Why?
|
| State Government | 1 | 2006 | 13 | 0.070 |
Why?
|
| Social Change | 1 | 2006 | 17 | 0.070 |
Why?
|
| Culture | 1 | 2007 | 173 | 0.070 |
Why?
|
| Vaccination | 2 | 2021 | 288 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 189 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2006 | 80 | 0.070 |
Why?
|
| Social Environment | 1 | 2007 | 207 | 0.070 |
Why?
|
| Maternal Mortality | 1 | 2005 | 13 | 0.070 |
Why?
|
| Infertility, Female | 1 | 2005 | 24 | 0.070 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 104 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 144 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 87 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2005 | 73 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 441 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 381 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 126 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 182 | 0.060 |
Why?
|
| Public Health | 1 | 2007 | 372 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2007 | 454 | 0.060 |
Why?
|
| Sociology, Medical | 1 | 2003 | 7 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 446 | 0.060 |
Why?
|
| Perforin | 1 | 2002 | 10 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 5 | 0.060 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Reproductive History | 1 | 2023 | 19 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 21 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 32 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.050 |
Why?
|
| Parity | 1 | 2023 | 46 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2002 | 50 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 87 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 17 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2023 | 138 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 40 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 26 | 0.050 |
Why?
|
| Mammography | 2 | 2019 | 188 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 420 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 148 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 156 | 0.050 |
Why?
|
| Exercise | 1 | 2007 | 613 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2002 | 89 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 159 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 185 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 17 | 0.050 |
Why?
|
| Mortality | 1 | 2022 | 145 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 307 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 211 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 502 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 259 | 0.050 |
Why?
|
| Research | 1 | 2022 | 163 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 290 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 28 | 0.050 |
Why?
|
| Family | 1 | 2021 | 173 | 0.040 |
Why?
|
| Smoking | 1 | 2006 | 940 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 455 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2019 | 35 | 0.040 |
Why?
|
| Cytokines | 1 | 2002 | 602 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2019 | 66 | 0.040 |
Why?
|
| Time Factors | 1 | 2002 | 1742 | 0.040 |
Why?
|
| Population Groups | 1 | 2017 | 56 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 661 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2016 | 36 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2021 | 1418 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 534 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 78 | 0.030 |
Why?
|
| Colorimetry | 1 | 2016 | 40 | 0.030 |
Why?
|
| Health Education | 2 | 2012 | 338 | 0.030 |
Why?
|
| Cameroon | 1 | 2015 | 38 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 935 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 803 | 0.030 |
Why?
|
| Marriage | 1 | 2013 | 16 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 217 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 859 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 304 | 0.030 |
Why?
|
| Counseling | 1 | 2013 | 116 | 0.030 |
Why?
|
| Vaginosis, Bacterial | 1 | 2012 | 6 | 0.030 |
Why?
|
| Government Programs | 1 | 2012 | 29 | 0.030 |
Why?
|
| Probiotics | 1 | 2012 | 25 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2011 | 16 | 0.030 |
Why?
|
| Risk | 1 | 2011 | 267 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 394 | 0.020 |
Why?
|
| Bacteria | 1 | 2012 | 255 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 436 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 4 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 12 | 0.020 |
Why?
|
| Cotinine | 1 | 2006 | 43 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 148 | 0.020 |
Why?
|
| Health Priorities | 1 | 2006 | 19 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 16 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 47 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 37 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2005 | 34 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 143 | 0.020 |
Why?
|
| Cisplatin | 1 | 2005 | 72 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 219 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 178 | 0.020 |
Why?
|